Using genomics to guide treatment for glioblastoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Aihara K, Mukasa A, Nagae G et al. Genetic and epigenetic stability of oligodendrogliomas at recurrence. Acta Neuropathol. Commun. 5, 18 (2017).
  MedlineGoogle Scholar
• 2 Bai H, Harmanci AS, Erson-Omay EZ et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat. Genet. 48, 59–66 (2015).
  MedlineGoogle Scholar
• 3 Ballester LY, Olar A, Roy-Chowdhuri S. Next-generation sequencing of central nervous systems tumors: the future of personalized patient management. Neuro. Oncol. 18, 308–310 (2016).
  Medline CASGoogle Scholar
• 4 Bjerke L, MacKay A, Nandhabalan M et al. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 3, 512–519 (2013).
  Medline CASGoogle Scholar
• 5 Bloch O, Lim M, Sughrue ME et al. Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy. Clin. Cancer Res. 23(14), 3575–3584 (2017).
  Medline CASGoogle Scholar
• 6 Blumenthal DT, Dvir A, Lossos A et al. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. J. Neurooncol. 130, 211–219 (2016).
  Medline CASGoogle Scholar
• 7 Blumenthal DT, Rankin C, Stelzer KJ et al. A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int. J. Clin. Oncol. 20, 650–658 (2015).
  Medline CASGoogle Scholar
• 8 Bolouri H, Zhao LP, Holland EC. Big data visualization identifies the multidimensional molecular landscape of human gliomas. Proc. Natl Acad. Sci. 113, 5394–5399 (2016).
  Medline CASGoogle Scholar
• 9 Brennan C, Momota H, Hambardzumyan D et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4, e7752 (2009).
  MedlineGoogle Scholar
• 10 Brennan CW, Verhaak RGW, McKenna A et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–477 (2013).
  Medline CASGoogle Scholar
• 11 Bush NAO, Butowski N. The effect of molecular diagnostics on the treatment of glioma. Curr. Oncol. Rep. 19, 26 (2017).
  MedlineGoogle Scholar
• 12 Butowski NA. Epidemiology and diagnosis of brain tumors. Contin. Lifelong Learn. Neurol. 21, 301–313 (2015).
  Google Scholar
• 13 Byron SA, Tran NL, Halperin RF et al. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clin. Cancer Res. 24, 295–305 (2018).
  Medline CASGoogle Scholar
• 14 Cairncross G, Wang M, Shaw E et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. 31, 337–343 (2013).
  Medline CASGoogle Scholar
• 15 Capper D, Jones DTW, Sill M et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469–474 (2018).
  Medline CASGoogle Scholar
• 16 Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J. Neurooncol. 114, 237–240 (2013).
  Medline CASGoogle Scholar
• 17 Chan AKY, Yao Y, Zhang Z et al. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod. Pathol. 28, 177–186 (2015).
  Medline CASGoogle Scholar
• 18 Chan AK, Han SJ, Choy W et al. Familial melanoma–astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. Clin. Neuropathol. 36, 213–221 (2017).
  MedlineGoogle Scholar
• 19 Chi AS, Batchelor TT, Kwak EL et al. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal–epithelial transition inhibitor. J. Clin. Oncol. 30, e30–e33 (2012).
  MedlineGoogle Scholar
• 20 Christensen BC, Smith AA, Zheng S et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl Cancer Inst. 103, 143–153 (2011).
  Medline CASGoogle Scholar
• 21 Christians A, Hartmann C, Benner A et al. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS ONE 7, e33449 (2012).
  Medline CASGoogle Scholar
• 22 Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).
  Medline CASGoogle Scholar
• 23 Darmanis S, Sloan SA, Croote D et al. Single-cell RNA-seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep. 21, 1399–1410 (2017).
  Medline CASGoogle Scholar
• 24 De Mattos-Arruda L, Mayor R, Ng CKY et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun. 6, 8839 (2015).
  Medline CASGoogle Scholar
• 25 Eckel-Passow JE, Lachance DH, Molinaro AM et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N. Engl. J. Med. 372, 2499–2508 (2015).
  Medline CASGoogle Scholar
• 26 Euskirchen P, Bielle F, Labreche K et al. Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. Acta Neuropathol. 134, 691–703 (2017).
  Medline CASGoogle Scholar
• 27 Fleming TP, Saxena A, Clark WC et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52, 4550–4553 (1992).
  Medline CASGoogle Scholar
• 28 Gutmann DH, James CD, Poyhonen M et al. Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology 61, 1397–1400 (2003).
  Medline CASGoogle Scholar
• 29 Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst. 97, 880–887 (2005).
  Medline CASGoogle Scholar
• 30 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  Medline CASGoogle Scholar
• 31 Hegi M, Diserens A. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005). • A large prospective trial demonstrating the prognostic importance of genomic information, specifically MGMT methylation, for patients with glioblastoma receiving temozolomide.
  Medline CASGoogle Scholar
• 32 Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell. Commun. Signal. 11, 97 (2013).
  MedlineGoogle Scholar
• 33 Hinkson IV, Davidsen TM, Klemm JD, Kerlavage AR, Kibbe WA. A comprehensive infrastructure for big data in cancer research: accelerating cancer research and precision medicine. Front. Cell Dev. Biol. 5, 83 (2017).
  MedlineGoogle Scholar
• 34 Hyman DM, Puzanov I, Subbiah V et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726–736 (2015).
  Medline CASGoogle Scholar
• 35 Jiao Y, Killela PJ, Reitman ZJ et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3, 709–722 (2012).
  MedlineGoogle Scholar
• 36 Johnson E, Dickerson KL, Connolly ID, Hayden Gephart M. Single-cell RNA-sequencing in glioma. Curr. Oncol. Rep. 20, 42 (2018).
  MedlineGoogle Scholar
• 37 Kaloshi G, Benouaich-Amiel A, Diakite F et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68, 1831–1836 (2007).
  Medline CASGoogle Scholar
• 38 Kessler T, Sahm F, Sadik A et al. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro. Oncol. 20, 367–379 (2018).
  Medline CASGoogle Scholar
• 39 Khuong-Quang DA, Buczkowicz P, Rakopoulos P et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 124, 439–447 (2012).
  Medline CASGoogle Scholar
• 40 Kline CN, Joseph NM, Grenert JP et al. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro. Oncol. 19, 699–709 (2017). • A recent publication highlighting the use of next-generation sequencing for pediatric patients and the potential of this technique to influence therapeutic decision-making.
  Medline CASGoogle Scholar
• 41 Koelsche C, Sahm F, Capper D et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 126, 907–915 (2013).
  Medline CASGoogle Scholar
• 42 Korshunov A, Ryzhova M, Hovestadt V et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 129, 669–678 (2015).
  Medline CASGoogle Scholar
• 43 Koschmann C, Calinescu AA, Nunez FJ et al. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci. Transl. Med. 8, 328ra28 (2016).
  MedlineGoogle Scholar
• 44 Kris MG, Johnson BE, Berry LD et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311, 1998–2006 (2014).
  Medline CASGoogle Scholar
• 45 Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
  Medline CASGoogle Scholar
• 46 Louis DN, Perry A, Reifenberger G et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803–820 (2016).
  MedlineGoogle Scholar
• 47 MacArthur KM, Kao GD, Chandrasekaran S et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 74, 2152–2159 (2014).
  Medline CASGoogle Scholar
• 48 Mahlokozera T, Vellimana AK, Li T et al. Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. Neuro. Oncol. 20, 472–483 (2018).
  Medline CASGoogle Scholar
• 49 Mazor T, Chesnelong C, Pankov A et al. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc. Natl Acad. Sci. USA 114, 10743–10748 (2017).
  Medline CASGoogle Scholar
• 50 Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012–2024 (2005).
  Medline CASGoogle Scholar
• 51 Mohammad F, Weissmann S, Leblanc B et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat. Med. 23, 483–492 (2017).
  Medline CASGoogle Scholar
• 52 Morrissy AS, Cavalli FMG, Remke M et al. Spatial heterogeneity in medulloblastoma. Nat. Genet. 49, 780–788 (2017).
  Medline CASGoogle Scholar
• 53 Müller C, Holtschmidt J, Auer M et al. Hematogenous dissemination of glioblastoma multiforme. Sci. Transl. Med. 6, 247ra101 (2014).
  MedlineGoogle Scholar
• 54 Müller S, Liu SJ, Di Lullo E et al. Single-cell sequencing maps gene expression to mutational phylogenies in PDGF- and EGF-driven gliomas. Mol. Syst. Biol. 12, 889 (2016).
  MedlineGoogle Scholar
• 55 Nakagawa Y, Sasaki H, Ohara K et al. Clinical and molecular prognostic factors for long-term survival of patients with glioblastomas in single-institutional consecutive cohort. World Neurosurg. 106, 165–173 (2017).
  MedlineGoogle Scholar
• 56 Nassiri F, Aldape K, Zadeh G. The multiforme of glioblastoma. Neuro. Oncol. 20, 437–438 (2018).
  MedlineGoogle Scholar
• 57 Nazarenko I, Hede SM, He X et al. PDGF and PDGF receptors in glioma. Ups J. Med. Sci. 117, 99–112 (2012).
  MedlineGoogle Scholar
• 58 Nicolaides TP, Li H, Solomon DA et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin. Cancer Res. 17, 7595–7604 (2011).
  Medline CASGoogle Scholar
• 59 Nikiforova MN, Wald AI, Melan MA et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro. Oncol. 18, 379–387 (2016). • One of the first studies demonstrating the feasibility of next-generation sequencing ‘hot spot’ panel for patients with glioblastoma.
  Medline CASGoogle Scholar
• 60 Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170, 1445–1453 (2007).
  Medline CASGoogle Scholar
• 61 Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancermedicalscience 8, 443 (2014).
  MedlineGoogle Scholar
• 62 Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008).
  Medline CASGoogle Scholar
• 63 Patel AP, Tirosh I, Trombetta JJ et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401 (2014). • First publication using single-cell RNA sequencing in glioblastoma to reveal the incredible intratumoral heterogeneity within a tumor.
  Medline CASGoogle Scholar
• 64 Picca A, Berzero G, Bielle F et al. FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas. Neurology 90, e2086–e2094 (2018).
  Medline CASGoogle Scholar
• 65 Popovici-Muller J, Lemieux RM, Artin E et al. Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med. Chem. Lett. 9, 300–305 (2018).
  Medline CASGoogle Scholar
• 66 Prados MD, Byron SA, Tran NL et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro. Oncol. 17, 1051–1063 (2015). • Review of the challenges facing molecular profiling for glioblastoma and some selected examples of targeted treatments.
  Medline CASGoogle Scholar
• 67 Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A. Glioma IDH1 mutation patterns off the beaten track. Neuropathol. Appl. Neurobiol. 37, 428–430 (2011).
  Medline CASGoogle Scholar
• 68 Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA- methyltranferase in a series of 100. Cancer 118, 4201–4211 (2012).
  Medline CASGoogle Scholar
• 69 Ravi A, Molinaro A, Han SJ, Chehab F, Berger MS, Butowski N. PATH-08. The prognostic value of a novel quantitative MGMT promoter methylation score for patients with glioblastoma. Neuro. Oncol. 19, vi172–vi172 (2017).
  Google Scholar
• 70 Reardon DA, Schuster J, Tran DD et al. ReACT: long-term survival from a randomized Phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. J. Clin. Oncol. 33, Abstract 2009 (2015).
  Google Scholar
• 71 Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 14, 258 (2014).
  MedlineGoogle Scholar
• 72 Sahm F, Schrimpf D, Jones DTW et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 131, 903–910 (2016).
  Medline CASGoogle Scholar
• 73 Schulte A, Liffers K, Kathagen A et al. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ. Neuro. Oncol. 15, 1289–1301 (2013).
  Medline CASGoogle Scholar
• 74 Schuster J, Lai RK, Recht LD et al. A Phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro. Oncol. 17, 854–861 (2015).
  Medline CASGoogle Scholar
• 75 See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res. 72, 3350–3359 (2012).
  Medline CASGoogle Scholar
• 76 See WL, Mukherjee J. Chapter 22: Targeting the RAS-RAF-MEK-ERK signaling pathway in gliomas A2. In: Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy (2nd Edition). Newton HB (Ed.). Academic Press, Cambridge, MA, USA, 323–332 (2018).
  Google Scholar
• 77 Shiraishi S, Tada K, Nakamura H et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 95, 249–257 (2002).
  Medline CASGoogle Scholar
• 78 Sottoriva A, Spiteri I, Piccirillo SGM et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl Acad. Sci. USA 110, 4009–14 (2013).
  Medline CASGoogle Scholar
• 79 Sullivan JP, Nahed BV, Madden MW et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 4, 1299–1309 (2014).
  Medline CASGoogle Scholar
• 80 Takahashi M, Miki S, Fukuoka K et al. OS01.5 Development of TERT-targeting therapy using eribulin mesylate in mouse glioblastoma model. Neuro. Oncol. 19, iii2 (2017).
  Google Scholar
• 81 Tamborero D, Rubio-Perez C, Deu-Pons J et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 10 (2018). • Introduces the Cancer Genome Interpreter, a platform that automates the interpretation of cancer genomic sequencing.
  MedlineGoogle Scholar
• 82 Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann. Oncol. 28, 1457–1472 (2017).
  Medline CASGoogle Scholar
• 83 van den Bent MJ, Baumert B, Erridge SC et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a Phase 3, randomised, open-label intergroup study. Lancet 390, 1645–1653 (2017).
  Medline CASGoogle Scholar
• 84 Verhaak RGW, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110 (2010).
  Medline CASGoogle Scholar
• 85 Vivanco I, Robins H, Rohle D, Campos C. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2, 458–71 (2012).
  Medline CASGoogle Scholar
• 86 Wang X, Chen JX, Liu JP, You C, Liu YH, Mao Q. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. Ann. Surg. Oncol. 21, 1337–1344 (2014).
  MedlineGoogle Scholar
• 87 Weller M, Butowski N, Tran DD et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international Phase 3 trial. Lancet Oncol. 18, 1373–1385 (2017).
  Medline CASGoogle Scholar
• 88 Westphal M, Heese O, Steinbach JP et al. A randomised, open label Phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur. J. Cancer 51, 522–532 (2015). • Example of a Phase III clinical trial for a targeted glioblastoma therapy that failed to demonstrate a survival benefit.
  Medline CASGoogle Scholar
• 89 Wick W, Weller M, Van Den Bent M et al. MGMT testing – the challenges for biomarker-based glioma treatment. Nat. Rev. Neurol. 10, 372–385 (2014).
  Medline CASGoogle Scholar
• 90 Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).
  Medline CASGoogle Scholar
• 91 Yap Y-S, McPherson JR, Ong C-K et al. The NF1 gene revisited – from bench to bedside. Oncotarget 5, 5873–5892 (2014).
  MedlineGoogle Scholar
• 92 Yip S, Iafrate AJ, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J. Neuropathol. Exp. Neurol. 67, 1–15 (2008).
  Medline CASGoogle Scholar
• 93 Zacher A, Kaulich K, Stepanow S et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel. Brain Pathol. 27, 146–159 (2017).
  Medline CASGoogle Scholar
• 94 Zhang G-B, Cui X-L, Sui D-L et al. Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients. J. Neurooncol. 113, 251–258 (2013).
  Medline CASGoogle Scholar